✦ LIBER ✦

Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy

✍ Scribed by L.-C. Wang; E.-Q. Chen; J. Cao; L. Liu; J.-R. Wang; B.-J. Lei; H. Tang

Book ID: 108886315
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 111 KB
Volume: 17
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2009.01164.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy of lamivudine and ad

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

✍ Satoshi Shakado; Hiroshi Watanabe; Takashi Tanaka; Daisuke Morihara; Shinya Nish 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 251 KB

De novo combination of lamivudine and ad

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

✍ Li-Chun Wang; En-Qiang Chen; Jing Cao; Li Liu; Li Zheng; Da-Jiang Li; Lu Xu; Xue 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 243 KB

Increased risk of adefovir resistance in

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt

Adding-on versus switching-to adefovir t

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B

✍ Irene Rapti; Evangelini Dimou; Panayota Mitsoula; Stephanos J. Hadziyannis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAgnegative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment. Patients were allocated in 2 treatm

Efficacy of adefovir add-on lamivudine r

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B

✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Adefovir-based combination therapy with

Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B

✍ Soon Sun Kim; Jae Youn Cheong; Dami Lee; Myoung Hee Lee; Sun Pyo Hong; Soo-Ok Ki 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

This study evaluated the efficacy of adefovir (ADV) plus lamivudine (LAM) or ADV add-on therapy for patients with entecavir (ETV)-refractory hepatitis B infection. Twenty-nine ETVresistant and 8 patients with suboptimal response to ETV were enrolled. Twenty-seven patients received ADV þ LAM therapy